Alnylam Pharmaceuticals (ANLY) Bullish Stance Reiterated at Needham & Company Post Q1

May 9, 2014 8:30 AM EDT
Get Alerts ALNY Hot Sheet
Price: $38.96 -0.31%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ALNY Now!
Join SI Premium – FREE

Needham & Company analyst Alan Carr reiterated a Buy rating and $94 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) following Q1 results.

Carr comments, "Alnylam mgmt hosted a conference call yesterday to provide a quarterly update. The company has made a series of presentations tied to multiple programs over the last month, including patisiran (TTR), ALN-PCSsc (hypercholesterolemia), and ALN-AAT (alpha-1-antitrypsin deficiency). Data from the ALN-AT3 hemophilia and ALN-CC5 programs are expected soon. Broadly, these data construct a competitive profile for RNAi in several rare diseases. Later this year, we expect to have initial insight into patisiran impact on FAP clincal symptoms (Phase 2 OLE trial interim analysis). We believe the stock is undervalued given recent pullback, and we reiterate our BUY."

The firm lowered FY 2014 EPS from ($4.93) to ($5.35) and FY 2015 EPS from ($1.84) to ($1.96).

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $50.26 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment